Parmax Pharma Limited
Parmax Pharma Limited (PARMAX.BO) Stock Competitors & Peer Comparison
See (PARMAX.BO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PARMAX.BO | ₹33.67 | +0.00% | 116.1M | -3.98 | -₹7.80 | N/A |
| MEDPLUS.BO | ₹828.40 | -0.00% | 99.6B | 48.17 | ₹17.23 | N/A |
| MEDPLUS.NS | ₹830.50 | +0.00% | 99.5B | 48.01 | ₹17.27 | N/A |
| GUJTHEM.BO | ₹327.30 | +0.00% | 36.5B | 76.68 | ₹4.37 | +0.20% |
| SHUKRAPHAR.BO | ₹39.40 | +0.00% | 16.4B | -187.20 | -₹0.20 | +0.05% |
| KPL.BO | ₹1,453.65 | +0.00% | 14.8B | 26.16 | ₹54.47 | N/A |
| SASTASUNDR.BO | ₹285.00 | +0.00% | 9.1B | 35.07 | ₹8.18 | N/A |
| SASTASUNDR.NS | ₹285.45 | +0.00% | 9.1B | 34.83 | ₹8.18 | N/A |
| FREDUN.BO | ₹1,712.25 | +0.00% | 7.9B | 23.80 | ₹69.91 | +0.04% |
| BPLPHARMA.BO | ₹1,087.75 | +0.00% | 7.6B | -25.71 | -₹42.80 | +0.09% |
Stock Comparison
PARMAX.BO vs MEDPLUS.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, MEDPLUS.BO has a market cap of 99.6B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while MEDPLUS.BO trades at ₹828.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas MEDPLUS.BO's P/E ratio is 48.17. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to MEDPLUS.BO's ROE of +0.12%. Regarding short-term risk, PARMAX.BO is more volatile compared to MEDPLUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDPLUS.BO's competition here
PARMAX.BO vs MEDPLUS.NS Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, MEDPLUS.NS has a market cap of 99.5B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while MEDPLUS.NS trades at ₹830.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas MEDPLUS.NS's P/E ratio is 48.01. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, PARMAX.BO is more volatile compared to MEDPLUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDPLUS.NS's competition here
PARMAX.BO vs GUJTHEM.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, GUJTHEM.BO has a market cap of 36.5B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while GUJTHEM.BO trades at ₹327.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas GUJTHEM.BO's P/E ratio is 76.68. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, PARMAX.BO is less volatile compared to GUJTHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GUJTHEM.BO's competition here
PARMAX.BO vs SHUKRAPHAR.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SHUKRAPHAR.BO has a market cap of 16.4B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SHUKRAPHAR.BO trades at ₹39.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SHUKRAPHAR.BO's P/E ratio is -187.20. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, PARMAX.BO is less volatile compared to SHUKRAPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SHUKRAPHAR.BO's competition here
PARMAX.BO vs KPL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, KPL.BO has a market cap of 14.8B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while KPL.BO trades at ₹1,453.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas KPL.BO's P/E ratio is 26.16. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, PARMAX.BO is less volatile compared to KPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check KPL.BO's competition here
PARMAX.BO vs SASTASUNDR.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SASTASUNDR.BO has a market cap of 9.1B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SASTASUNDR.BO trades at ₹285.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SASTASUNDR.BO's P/E ratio is 35.07. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, PARMAX.BO is more volatile compared to SASTASUNDR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SASTASUNDR.BO's competition here
PARMAX.BO vs SASTASUNDR.NS Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SASTASUNDR.NS has a market cap of 9.1B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SASTASUNDR.NS trades at ₹285.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SASTASUNDR.NS's P/E ratio is 34.83. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, PARMAX.BO is more volatile compared to SASTASUNDR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SASTASUNDR.NS's competition here
PARMAX.BO vs FREDUN.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, FREDUN.BO has a market cap of 7.9B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while FREDUN.BO trades at ₹1,712.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas FREDUN.BO's P/E ratio is 23.80. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, PARMAX.BO is less volatile compared to FREDUN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check FREDUN.BO's competition here
PARMAX.BO vs BPLPHARMA.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, BPLPHARMA.BO has a market cap of 7.6B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while BPLPHARMA.BO trades at ₹1,087.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas BPLPHARMA.BO's P/E ratio is -25.71. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to BPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BPLPHARMA.BO's competition here
PARMAX.BO vs ANUHPHR.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ANUHPHR.BO has a market cap of 7.5B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ANUHPHR.BO trades at ₹75.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ANUHPHR.BO's P/E ratio is 18.01. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, PARMAX.BO is more volatile compared to ANUHPHR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check ANUHPHR.BO's competition here
PARMAX.BO vs PRAVEG.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, PRAVEG.BO has a market cap of 7.1B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while PRAVEG.BO trades at ₹274.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas PRAVEG.BO's P/E ratio is -287.29. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to PRAVEG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PRAVEG.BO's competition here
PARMAX.BO vs SGRL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SGRL.BO has a market cap of 6.5B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SGRL.BO trades at ₹506.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SGRL.BO's P/E ratio is 35.75. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, PARMAX.BO is more volatile compared to SGRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SGRL.BO's competition here
PARMAX.BO vs SUDARSHAN.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SUDARSHAN.BO has a market cap of 6.4B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SUDARSHAN.BO trades at ₹26.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SUDARSHAN.BO's P/E ratio is 31.46. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SUDARSHAN.BO's ROE of +0.16%. Regarding short-term risk, PARMAX.BO is more volatile compared to SUDARSHAN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SUDARSHAN.BO's competition here
PARMAX.BO vs ALBERTDA.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ALBERTDA.BO's ROE of +0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to ALBERTDA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ALBERTDA.BO's competition here
PARMAX.BO vs VIKRAMTH.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, VIKRAMTH.BO has a market cap of 4.8B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while VIKRAMTH.BO trades at ₹154.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas VIKRAMTH.BO's P/E ratio is 14.02. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, PARMAX.BO is less volatile compared to VIKRAMTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VIKRAMTH.BO's competition here
PARMAX.BO vs JENBURPH.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, JENBURPH.BO has a market cap of 4.5B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while JENBURPH.BO trades at ₹1,033.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas JENBURPH.BO's P/E ratio is 13.96. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, PARMAX.BO is less volatile compared to JENBURPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check JENBURPH.BO's competition here
PARMAX.BO vs TLL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, TLL.BO has a market cap of 3.1B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while TLL.BO trades at ₹256.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas TLL.BO's P/E ratio is 21.13. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, PARMAX.BO is less volatile compared to TLL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TLL.BO's competition here
PARMAX.BO vs GENNEX.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, GENNEX.BO has a market cap of 2.8B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while GENNEX.BO trades at ₹11.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas GENNEX.BO's P/E ratio is 15.18. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to GENNEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GENNEX.BO's competition here
PARMAX.BO vs ZENOTECH.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ZENOTECH.BO has a market cap of 2.8B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ZENOTECH.BO trades at ₹45.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ZENOTECH.BO's P/E ratio is 84.29. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to ZENOTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENOTECH.BO's competition here
PARMAX.BO vs KERALAYUR.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, KERALAYUR.BO has a market cap of 2.8B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while KERALAYUR.BO trades at ₹231.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas KERALAYUR.BO's P/E ratio is -11.15. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, PARMAX.BO is more volatile compared to KERALAYUR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check KERALAYUR.BO's competition here
PARMAX.BO vs BDH.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, BDH.BO has a market cap of 2.5B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while BDH.BO trades at ₹418.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas BDH.BO's P/E ratio is 23.88. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, PARMAX.BO is less volatile compared to BDH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BDH.BO's competition here
PARMAX.BO vs SANJIVIN.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SANJIVIN.BO has a market cap of 2.4B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SANJIVIN.BO trades at ₹195.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SANJIVIN.BO's P/E ratio is 32.86. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SANJIVIN.BO's ROE of +0.22%. Regarding short-term risk, PARMAX.BO is less volatile compared to SANJIVIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SANJIVIN.BO's competition here
PARMAX.BO vs SYSCHEM.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SYSCHEM.BO has a market cap of 2.2B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SYSCHEM.BO trades at ₹51.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SYSCHEM.BO's P/E ratio is 34.74. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, PARMAX.BO is more volatile compared to SYSCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SYSCHEM.BO's competition here
PARMAX.BO vs AMBALALSA.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, AMBALALSA.BO has a market cap of 2B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while AMBALALSA.BO trades at ₹26.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas AMBALALSA.BO's P/E ratio is 21.18. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to AMBALALSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check AMBALALSA.BO's competition here
PARMAX.BO vs TRANSCHEM.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, TRANSCHEM.BO has a market cap of 2B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while TRANSCHEM.BO trades at ₹156.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas TRANSCHEM.BO's P/E ratio is 68.56. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to TRANSCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check TRANSCHEM.BO's competition here
PARMAX.BO vs OXYGENTAPH.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, OXYGENTAPH.BO has a market cap of 1.9B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while OXYGENTAPH.BO trades at ₹52.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas OXYGENTAPH.BO's P/E ratio is -10.91. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to OXYGENTAPH.BO's ROE of +0.65%. Regarding short-term risk, PARMAX.BO is less volatile compared to OXYGENTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check OXYGENTAPH.BO's competition here
PARMAX.BO vs AUROLAB.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, AUROLAB.BO has a market cap of 1.8B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while AUROLAB.BO trades at ₹298.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas AUROLAB.BO's P/E ratio is 56.09. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, PARMAX.BO is less volatile compared to AUROLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check AUROLAB.BO's competition here
PARMAX.BO vs KIMIABL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, KIMIABL.BO has a market cap of 1.6B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while KIMIABL.BO trades at ₹33.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to KIMIABL.BO's ROE of +1.10%. Regarding short-term risk, PARMAX.BO is less volatile compared to KIMIABL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check KIMIABL.BO's competition here
PARMAX.BO vs NATCAPSUQ.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, NATCAPSUQ.BO has a market cap of 1.6B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while NATCAPSUQ.BO trades at ₹160.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas NATCAPSUQ.BO's P/E ratio is -13.59. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, PARMAX.BO is more volatile compared to NATCAPSUQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check NATCAPSUQ.BO's competition here
PARMAX.BO vs CORALAB.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, CORALAB.BO has a market cap of 1.5B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while CORALAB.BO trades at ₹442.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas CORALAB.BO's P/E ratio is 8.81. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, PARMAX.BO is less volatile compared to CORALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CORALAB.BO's competition here
PARMAX.BO vs PARNAXLAB.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, PARNAXLAB.BO has a market cap of 1.5B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while PARNAXLAB.BO trades at ₹122.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas PARNAXLAB.BO's P/E ratio is 13.85. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, PARMAX.BO is more volatile compared to PARNAXLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check PARNAXLAB.BO's competition here
PARMAX.BO vs PANCHSHEEL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, PANCHSHEEL.BO has a market cap of 1.5B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while PANCHSHEEL.BO trades at ₹112.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas PANCHSHEEL.BO's P/E ratio is 12.09. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to PANCHSHEEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PANCHSHEEL.BO's competition here
PARMAX.BO vs SMRUTHIORG.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SMRUTHIORG.BO has a market cap of 1.3B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SMRUTHIORG.BO trades at ₹111.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SMRUTHIORG.BO's P/E ratio is 27.19. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, PARMAX.BO is more volatile compared to SMRUTHIORG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SMRUTHIORG.BO's competition here
PARMAX.BO vs PHARMAID.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, PHARMAID.BO has a market cap of 1.2B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while PHARMAID.BO trades at ₹34.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas PHARMAID.BO's P/E ratio is -9.90. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to PHARMAID.BO's ROE of -0.24%. Regarding short-term risk, PARMAX.BO is less volatile compared to PHARMAID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PHARMAID.BO's competition here
PARMAX.BO vs LACTOSE.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, LACTOSE.BO has a market cap of 1.2B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while LACTOSE.BO trades at ₹97.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas LACTOSE.BO's P/E ratio is 41.98. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is more volatile compared to LACTOSE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check LACTOSE.BO's competition here
PARMAX.BO vs TYCHE.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, TYCHE.BO has a market cap of 1.2B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while TYCHE.BO trades at ₹116.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas TYCHE.BO's P/E ratio is 12.26. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is more volatile compared to TYCHE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check TYCHE.BO's competition here
PARMAX.BO vs DENISCHEM.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, DENISCHEM.BO has a market cap of 1.1B. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while DENISCHEM.BO trades at ₹80.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas DENISCHEM.BO's P/E ratio is 15.44. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, PARMAX.BO is more volatile compared to DENISCHEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check DENISCHEM.BO's competition here
PARMAX.BO vs MERCURYLAB.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, MERCURYLAB.BO has a market cap of 978.7M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while MERCURYLAB.BO trades at ₹800.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas MERCURYLAB.BO's P/E ratio is 20.72. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is more volatile compared to MERCURYLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check MERCURYLAB.BO's competition here
PARMAX.BO vs MAKERSL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, MAKERSL.BO has a market cap of 867.7M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while MAKERSL.BO trades at ₹146.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas MAKERSL.BO's P/E ratio is 71.04. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to MAKERSL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MAKERSL.BO's competition here
PARMAX.BO vs CONCORD.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, CONCORD.BO has a market cap of 840.3M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while CONCORD.BO trades at ₹83.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas CONCORD.BO's P/E ratio is 145.60. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to CONCORD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CONCORD.BO's competition here
PARMAX.BO vs SOURCENTRL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SOURCENTRL.BO has a market cap of 824.6M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SOURCENTRL.BO trades at ₹126.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SOURCENTRL.BO's P/E ratio is 27.73. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, PARMAX.BO is more volatile compared to SOURCENTRL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SOURCENTRL.BO's competition here
PARMAX.BO vs BIBCL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, BIBCL.BO has a market cap of 786.7M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while BIBCL.BO trades at ₹18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas BIBCL.BO's P/E ratio is -4.82. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, PARMAX.BO is more volatile compared to BIBCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check BIBCL.BO's competition here
PARMAX.BO vs SUNLOC.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SUNLOC.BO has a market cap of 707.6M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SUNLOC.BO trades at ₹67.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SUNLOC.BO's P/E ratio is 24.73. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to SUNLOC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SUNLOC.BO's competition here
PARMAX.BO vs PHRMASI.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, PHRMASI.BO has a market cap of 696.3M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while PHRMASI.BO trades at ₹104.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas PHRMASI.BO's P/E ratio is 3.92. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, PARMAX.BO is less volatile compared to PHRMASI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PHRMASI.BO's competition here
PARMAX.BO vs BACPHAR.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, BACPHAR.BO has a market cap of 681.3M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while BACPHAR.BO trades at ₹47.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas BACPHAR.BO's P/E ratio is 128.30. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to BACPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BACPHAR.BO's competition here
PARMAX.BO vs GODAVARI.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, GODAVARI.BO has a market cap of 630.9M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while GODAVARI.BO trades at ₹85.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas GODAVARI.BO's P/E ratio is -93.09. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is more volatile compared to GODAVARI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check GODAVARI.BO's competition here
PARMAX.BO vs VISTAPH.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, VISTAPH.BO has a market cap of 466.6M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while VISTAPH.BO trades at ₹7.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas VISTAPH.BO's P/E ratio is -6.65. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, PARMAX.BO is less volatile compared to VISTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VISTAPH.BO's competition here
PARMAX.BO vs SHELTER.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SHELTER.BO has a market cap of 460.5M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SHELTER.BO trades at ₹41.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SHELTER.BO's P/E ratio is 7.36. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SHELTER.BO's ROE of +0.12%. Regarding short-term risk, PARMAX.BO is less volatile compared to SHELTER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SHELTER.BO's competition here
PARMAX.BO vs PANJON.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, PANJON.BO has a market cap of 437.7M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while PANJON.BO trades at ₹25.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas PANJON.BO's P/E ratio is 60.71. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is less volatile compared to PANJON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PANJON.BO's competition here
PARMAX.BO vs VRL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, VRL.BO has a market cap of 414.3M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while VRL.BO trades at ₹131.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas VRL.BO's P/E ratio is 11.07. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to VRL.BO's ROE of +0.12%. Regarding short-term risk, PARMAX.BO is less volatile compared to VRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VRL.BO's competition here
PARMAX.BO vs VEERHEALTH.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, VEERHEALTH.BO has a market cap of 396.4M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while VEERHEALTH.BO trades at ₹19.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas VEERHEALTH.BO's P/E ratio is 82.58. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to VEERHEALTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VEERHEALTH.BO's competition here
PARMAX.BO vs SANDUPHQ.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SANDUPHQ.BO has a market cap of 354.9M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SANDUPHQ.BO trades at ₹36.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SANDUPHQ.BO's P/E ratio is 21.87. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is more volatile compared to SANDUPHQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SANDUPHQ.BO's competition here
PARMAX.BO vs ROOPAIND.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ROOPAIND.BO has a market cap of 349.1M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ROOPAIND.BO trades at ₹46.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ROOPAIND.BO's P/E ratio is 18.11. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, PARMAX.BO is less volatile compared to ROOPAIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ROOPAIND.BO's competition here
PARMAX.BO vs DECCAN.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, DECCAN.BO has a market cap of 327.5M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while DECCAN.BO trades at ₹13.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas DECCAN.BO's P/E ratio is 24.53. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to DECCAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check DECCAN.BO's competition here
PARMAX.BO vs ANG.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ANG.BO has a market cap of 317.1M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ANG.BO trades at ₹24.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ANG.BO's P/E ratio is -2.60. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, PARMAX.BO is more volatile compared to ANG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check ANG.BO's competition here
PARMAX.BO vs GUJTERC.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, GUJTERC.BO has a market cap of 299.2M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while GUJTERC.BO trades at ₹41.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas GUJTERC.BO's P/E ratio is -21.56. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, PARMAX.BO is less volatile compared to GUJTERC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GUJTERC.BO's competition here
PARMAX.BO vs MEDICAPQ.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, MEDICAPQ.BO has a market cap of 294.5M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while MEDICAPQ.BO trades at ₹23.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas MEDICAPQ.BO's P/E ratio is -5.23. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDICAPQ.BO's competition here
PARMAX.BO vs CRSTCHM.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, CRSTCHM.BO has a market cap of 274.1M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while CRSTCHM.BO trades at ₹94.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas CRSTCHM.BO's P/E ratio is 13.95. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, PARMAX.BO is less volatile compared to CRSTCHM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CRSTCHM.BO's competition here
PARMAX.BO vs TRIMURTHI.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to TRIMURTHI.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to TRIMURTHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check TRIMURTHI.BO's competition here
PARMAX.BO vs ASRL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ASRL.BO has a market cap of 223.4M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ASRL.BO trades at ₹8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ASRL.BO's P/E ratio is 13.15. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ASRL.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to ASRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ASRL.BO's competition here
PARMAX.BO vs ISHITADR.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ISHITADR.BO has a market cap of 212.8M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ISHITADR.BO trades at ₹71.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ISHITADR.BO's P/E ratio is 23.96. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ISHITADR.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is more volatile compared to ISHITADR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check ISHITADR.BO's competition here
PARMAX.BO vs CHEMOPH.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to CHEMOPH.BO's ROE of -0.87%. Regarding short-term risk, PARMAX.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CHEMOPH.BO's competition here
PARMAX.BO vs ZENITHHE.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ZENITHHE.BO has a market cap of 179.5M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ZENITHHE.BO trades at ₹3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ZENITHHE.BO's P/E ratio is -334.00. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, PARMAX.BO is more volatile compared to ZENITHHE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENITHHE.BO's competition here
PARMAX.BO vs ZENLABS.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ZENLABS.BO has a market cap of 136.9M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ZENLABS.BO trades at ₹19.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ZENLABS.BO's P/E ratio is -7.40. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ZENLABS.BO's ROE of -0.18%. Regarding short-term risk, PARMAX.BO is less volatile compared to ZENLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENLABS.BO's competition here
PARMAX.BO vs NORRIS.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, NORRIS.BO has a market cap of 133.3M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while NORRIS.BO trades at ₹13.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to NORRIS.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to NORRIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check NORRIS.BO's competition here
PARMAX.BO vs EMMESSA.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, EMMESSA.BO has a market cap of 129.9M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while EMMESSA.BO trades at ₹26.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas EMMESSA.BO's P/E ratio is 59.09. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to EMMESSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check EMMESSA.BO's competition here
PARMAX.BO vs COLINZ.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, COLINZ.BO has a market cap of 126M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while COLINZ.BO trades at ₹51.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas COLINZ.BO's P/E ratio is 25.51. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is more volatile compared to COLINZ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check COLINZ.BO's competition here
PARMAX.BO vs CHCL.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, CHCL.BO has a market cap of 125.2M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while CHCL.BO trades at ₹5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, PARMAX.BO is more volatile compared to CHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check CHCL.BO's competition here
PARMAX.BO vs DESHRAK.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, DESHRAK.BO has a market cap of 119.7M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while DESHRAK.BO trades at ₹27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas DESHRAK.BO's P/E ratio is 32.53. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to DESHRAK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check DESHRAK.BO's competition here
PARMAX.BO vs SHAMROIN.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, SHAMROIN.BO has a market cap of 110.6M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while SHAMROIN.BO trades at ₹20.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas SHAMROIN.BO's P/E ratio is -22.89. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to SHAMROIN.BO's ROE of -0.68%. Regarding short-term risk, PARMAX.BO is more volatile compared to SHAMROIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SHAMROIN.BO's competition here
PARMAX.BO vs BERLDRG.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, BERLDRG.BO has a market cap of 110.1M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while BERLDRG.BO trades at ₹21.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas BERLDRG.BO's P/E ratio is 723.33. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, PARMAX.BO is more volatile compared to BERLDRG.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check BERLDRG.BO's competition here
PARMAX.BO vs TRINITYLEA.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, TRINITYLEA.BO has a market cap of 101.1M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while TRINITYLEA.BO trades at ₹13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas TRINITYLEA.BO's P/E ratio is -255.40. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to TRINITYLEA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TRINITYLEA.BO's competition here
PARMAX.BO vs ADLINE.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, ADLINE.BO has a market cap of 86.3M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while ADLINE.BO trades at ₹14.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, PARMAX.BO is more volatile compared to ADLINE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check ADLINE.BO's competition here
PARMAX.BO vs DECIPHER.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, DECIPHER.BO has a market cap of 85.7M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while DECIPHER.BO trades at ₹8.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas DECIPHER.BO's P/E ratio is -1.06. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to DECIPHER.BO's ROE of -0.38%. Regarding short-term risk, PARMAX.BO is less volatile compared to DECIPHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check DECIPHER.BO's competition here
PARMAX.BO vs VIVANZA.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, VIVANZA.BO has a market cap of 84M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while VIVANZA.BO trades at ₹2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas VIVANZA.BO's P/E ratio is -26.25. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, PARMAX.BO is more volatile compared to VIVANZA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check VIVANZA.BO's competition here
PARMAX.BO vs HINDBIO.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, HINDBIO.BO has a market cap of 81.4M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while HINDBIO.BO trades at ₹7.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas HINDBIO.BO's P/E ratio is 52.93. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to HINDBIO.BO's ROE of +0.17%. Regarding short-term risk, PARMAX.BO is less volatile compared to HINDBIO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check HINDBIO.BO's competition here
PARMAX.BO vs EVOQ.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, EVOQ.BO has a market cap of 80.2M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while EVOQ.BO trades at ₹3.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas EVOQ.BO's P/E ratio is 4.54. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to EVOQ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check EVOQ.BO's competition here
PARMAX.BO vs GANGAPHARM.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while GANGAPHARM.BO trades at ₹12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is more volatile compared to GANGAPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check GANGAPHARM.BO's competition here
PARMAX.BO vs KOBO.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, KOBO.BO has a market cap of 68.9M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while KOBO.BO trades at ₹2.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas KOBO.BO's P/E ratio is -1.36. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to KOBO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check KOBO.BO's competition here
PARMAX.BO vs TIAANC.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, TIAANC.BO has a market cap of 61.6M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while TIAANC.BO trades at ₹6.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas TIAANC.BO's P/E ratio is -60.00. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to TIAANC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TIAANC.BO's competition here
PARMAX.BO vs PATIDAR.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, PATIDAR.BO has a market cap of 52M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while PATIDAR.BO trades at ₹9.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas PATIDAR.BO's P/E ratio is -19.29. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to PATIDAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check PATIDAR.BO's competition here
PARMAX.BO vs WELCURE.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, WELCURE.BO has a market cap of 38.2M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while WELCURE.BO trades at ₹0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas WELCURE.BO's P/E ratio is 1.17. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, PARMAX.BO is less volatile compared to WELCURE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check WELCURE.BO's competition here
PARMAX.BO vs TMTIND-B1.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, TMTIND-B1.BO has a market cap of 34.5M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while TMTIND-B1.BO trades at ₹6.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas TMTIND-B1.BO's P/E ratio is -7.83. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, PARMAX.BO is more volatile compared to TMTIND-B1.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check TMTIND-B1.BO's competition here
PARMAX.BO vs FABINO.BO Comparison February 2026
PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PARMAX.BO stands at 116.1M. In comparison, FABINO.BO has a market cap of 27.5M. Regarding current trading prices, PARMAX.BO is priced at ₹33.67, while FABINO.BO trades at ₹13.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PARMAX.BO currently has a P/E ratio of -3.98, whereas FABINO.BO's P/E ratio is -17.95. In terms of profitability, PARMAX.BO's ROE is +2.05%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to FABINO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check FABINO.BO's competition here